- Home
- XGN
XGN
Exagen Inc.
as 12-18-2024 10:44am EST
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | VISTA |
| Market Cap: | 72.3M | IPO Year: | 2019 |
| Target Price: | $7.00 | AVG Volume (30 days): | 189.6K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.30 - $6.22 | Next Earning Date: | 11-12-2024 |
| Revenue: | $55,751,000 | Revenue Growth: | 8.00% |
| Revenue Growth (this year): | 6.74% | Revenue Growth (next year): | 17.32% |
Stock Insider Trading Activity of Exagen Inc. (XGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| NMSIC Co-Investment Fund, L.P. | XGN | 10% Owner | Nov 20 '24 | Sell | $3.30 | 200,000 | $660,040.00 | 2,108,958 | |
| Black Jeffrey G. | XGN | Chief Financial Officer | Nov 15 '24 | Buy | $2.98 | 22,298 | $66,448.04 | 274,492 | |
| ABALLI JOHN | XGN | President and CEO | Nov 14 '24 | Buy | $2.81 | 24,305 | $68,297.05 | 689,799 |
Latest Exagen Inc. News
XGN Breaking Stock News: Dive into XGN Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
Simply Wall St.
8 days ago
Data Storage And 2 Other US Penny Stocks To Watch
Simply Wall St.
a month ago
Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
GlobeNewswire
a month ago
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
GlobeNewswire
a month ago
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
GuruFocus.com
a month ago
Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ...
Thomson Reuters StreetEvents
a month ago
Q3 2024 Exagen Inc Earnings Call
Zacks
a month ago
Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates
Compare XGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "XGN Exagen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.